These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 2863940)

  • 1. Somatostatin agonists and antagonists--peptide control of growth hormone secretion.
    Coy DH; Murphy WA; Lance VA; Hocart SJ; Sueiras-Diaz J; Mezo I
    Adv Exp Med Biol; 1985; 188():325-37. PubMed ID: 2863940
    [No Abstract]   [Full Text] [Related]  

  • 2. Somatostatin analogs with improved oral bioavailability.
    Nutt RF; Colton CD; Veber DF; Slater EL; Saperstein R
    Klin Wochenschr; 1986; 64 Suppl 7():71-3. PubMed ID: 2882053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies on the mechanism of somatostatin action on insulin release. V. Effect of somatostatin analogues on arginine induced release of insulin and glucagon from the perfused rat pancreas.
    Efendić S; Lins PE; Luft R; Sievertsson H; Westin-Sjödal G
    Acta Endocrinol (Copenh); 1977 Jul; 85(3):579-86. PubMed ID: 194446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dissociation of somatostatin effects. Peptides inhibiting the release of growth hormone but not glucagon or insulin in rats.
    Grant N; Clark D; Garsky V; Jaunakais I; McGregor W; Sarantakis D
    Life Sci; 1976 Sep; 19(5):629-31. PubMed ID: 957897
    [No Abstract]   [Full Text] [Related]  

  • 5. Relative effects of somatostatin and two somatostatin analogues on the release of insulin, glucagon and growth hormone.
    Efendić S; Luft R; Sievertsson H
    FEBS Lett; 1975 Oct; 58(1):302-5. PubMed ID: 1225595
    [No Abstract]   [Full Text] [Related]  

  • 6. Observations on the growth hormone, insulin, and glucagon release-inhibiting activities of somatostatin analogues.
    Coy DH; Meyers C; Arimura A; Schally AV; Redding TW
    Metabolism; 1978 Sep; 27(9 Suppl 1):1407-10. PubMed ID: 683009
    [No Abstract]   [Full Text] [Related]  

  • 7. Functional receptors for the insulinotropic hormone glucagon-like peptide-I(7-37) on a somatostatin secreting cell line.
    Fehmann HC; Habener JF
    FEBS Lett; 1991 Feb; 279(2):335-40. PubMed ID: 1672112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologic and immunologic activities and applications of somatostatin analogs.
    Vale W; Rivier J; Ling N; Brown M
    Metabolism; 1978 Sep; 27(9 Suppl 1):1391-401. PubMed ID: 210361
    [No Abstract]   [Full Text] [Related]  

  • 9. Somatostatin antagonist analog increases GH, insulin, and glucagon release in the rat.
    Fries JL; Murphy WA; Sueiras-Diaz J; Coy DH
    Peptides; 1982; 3(5):811-4. PubMed ID: 6129618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on growth hormone secretion. VII. Effects of somatostatin on plasma GH, insulin, and glucagon in sheep.
    Bryce D; Yeh M; Funderburk C; Todd H; Hertelendy F
    Diabetes; 1975 Sep; 24(9):842-50. PubMed ID: 169176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatostatin: analogs with selected biological activities.
    Brown M; Rivier J; Vale W
    Science; 1977 Jun; 196(4297):1467-9. PubMed ID: 867045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagon releasing activity of a cyclic peptide related to somatostatin.
    Lyle TA; Freidinger RM; Nutt RF; Homnick CF; Saperstein R; Veber DF
    Int J Pept Protein Res; 1987 Feb; 29(2):244-9. PubMed ID: 2883151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Phe4]somatostatin: a potent, selective inhibitor of growth hormone release.
    Meyers CA; Coy DH; Murphy WA; Redding TW; Arimura A; Schally AV
    Proc Natl Acad Sci U S A; 1980 Jan; 77(1):577-9. PubMed ID: 6987657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective effects of somatostatin-14, -25 and -28 on in vitro insulin and glucagon secretion.
    Mandarino L; Stenner D; Blanchard W; Nissen S; Gerich J; Ling N; Brazeau P; Bohlen P; Esch F; Guillemin R
    Nature; 1981 May; 291(5810):76-7. PubMed ID: 6112710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatostatin: physiological and clinical significance.
    Guillemin R; Gerich JE
    Annu Rev Med; 1976; 27():379-88. PubMed ID: 779605
    [No Abstract]   [Full Text] [Related]  

  • 16. Conformationally restricted bicyclic analogs of somatostatin.
    Veber DF; Holly FW; Paleveda WJ; Nutt RF; Bergstrand SJ; Torchiana M; Glitzer MS; Saperstein R; Hirschmann R
    Proc Natl Acad Sci U S A; 1978 Jun; 75(6):2636-40. PubMed ID: 208068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A super active cyclic hexapeptide analog of somatostatin.
    Veber DF; Saperstein R; Nutt RF; Freidinger RM; Brady SF; Curley P; Perlow DS; Paleveda WJ; Colton CD; Zacchei AG
    Life Sci; 1984 Apr; 34(14):1371-8. PubMed ID: 6143233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis of a nonreducible cyclic analog of somatostatin having only growth hormone release inhibiting activity.
    Garsky VM; Clark DE; Grant NH
    Biochem Biophys Res Commun; 1976 Dec; 73(4):911-6. PubMed ID: 15625860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of cylic and linear forms of somatostatin in the inhibiton of growth hormone, insulin and glucagon Secretion.
    Leblanc H; Yen SS
    J Clin Endocrinol Metab; 1975 May; 40(5):906-8. PubMed ID: 1127098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Central nervous system actions of somatostatin-related peptides.
    Brown MR; Fisher LA
    Adv Exp Med Biol; 1985; 188():217-28. PubMed ID: 2863933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.